NewsBenzinga알파타우, 일요일 발표···재발성 교모세포종 환자 8명 대상 알파 다트 치료제 100% 타당성 입증, 평가 가능한 6명 중 5명 완전 반응, 1명 부분 반응, 예기치 않은 심각한 부작용 없어 알파타우, 일요일 발표···재발성 교모세포종 환자 8명 대상 알파 다트 치료제 100% 타당성 입증, 평가 가능한 6명 중 5명 완전 반응, 1명 부분 반응, 예기치 않은 심각한 부작용 없어 Benzinga 2026.11.16 05:20 (GMT+0) Open on Benzinga Other news Reported Sunday, Alpha Tau’s Alpha DaRT Achieves 100% Feasibility In 8 Recurrent Glioblastoma Patients, With Five Complete Responses And One Partial Response Among Six Evaluable Patients And No Unanticipated Serious Adverse Events Reported Sunday, IDEAYA Nominates IDE101, Potential First-In-Class Dual CDK Inhibitor Targeting CDKN2A-Deficiency In Solid Tumors, With IND Filing Planned For H1 2027 Nasdaq Falls Over 200 Points but Still Posts Weekly Gain; Investor Sentiment Weakens as Fear & Greed Index Remains in 'Fear' Zone Tyson Foods, Aramark and 3 Stocks to Watch Heading Into Monday HSBC Downgrades Nvidia to Hold, Cuts Price Target From $365 to $170 Flight Meltdown Enters Day 3: JetBlue, American Still Scrambling After FAA Router Failure
Reported Sunday, Alpha Tau’s Alpha DaRT Achieves 100% Feasibility In 8 Recurrent Glioblastoma Patients, With Five Complete Responses And One Partial Response Among Six Evaluable Patients And No Unanticipated Serious Adverse Events
Reported Sunday, IDEAYA Nominates IDE101, Potential First-In-Class Dual CDK Inhibitor Targeting CDKN2A-Deficiency In Solid Tumors, With IND Filing Planned For H1 2027
Nasdaq Falls Over 200 Points but Still Posts Weekly Gain; Investor Sentiment Weakens as Fear & Greed Index Remains in 'Fear' Zone